<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443751</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1702-I-102</org_study_id>
    <nct_id>NCT04443751</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase I, Multicenter, Open-label Study of SHR-1702 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and preliminary efficacy of escalating doses of SHR-1702
      monotherapy in relapsed/refractory AML and intermediate-high risk MDS
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SHR-1702 monotherapy in patients with AML or MDS.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with the type, frequency, and severity of adverse events (AEs) as a measure of safety and tolerability of SHR-1702 monotherapy in AML and MDS patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of SHR-1702 monotherapy in patients with AML or MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration (Cmax) of SHR-1702 monotherapy in patients with AML or MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by the presence of anti-drug antibodies</measure>
    <time_frame>2 years</time_frame>
    <description>Anti SHR-1702 antibodies will be tested frequently</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile as assessed by receptor occupancy</measure>
    <time_frame>2 years</time_frame>
    <description>SHR-1702 receptor occupation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate（ORR）for SHR-1702 in AML based on IWG2003 or high risk MDS based on IWG2006</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best of Response（BOR）for SHR-1702 in AML or high risk MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival（PFS) for SHR-1702 in AML or high risk MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS) for SHR-1702 in AML or high risk MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>AML</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>SHR-1702 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1702</intervention_name>
    <description>SHR-1702 monotherapy, administered IV</description>
    <arm_group_label>SHR-1702 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female.

          2. ≥18 years of age.

          3. Refractory/Relapsed AML, or failed to achieve complete remission after 2 cycles of
             induction therapy.

          4. Intermediate, High and very high risk MDS according to the revised International
             Prognostic Scoring System (IPSS-R) who have failed prior therapies, such as
             azacitidine and decitabine (Scoring≥3.5).

          5. Life expectancy≥12 months.

          6. With Adequate hematologic and organ function

          7. Signed inform consent form

        Exclusion Criteria:

          1. With a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan.

          2. With significant cardiovascular disease.

          3. With a history of autoimmune disease.

          4. Subjects with a condition requiring systemic treatment with either corticosteroids
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of first administration of study treatment. Inhaled or topical steroids, and
             adrenal replacement steroid are permitted in the absence of active autoimmune disease.

          5. Positive test result for human immunodeficiency virus (HIV); Active hepatitis B or
             hepatitis C.

          6. Active or untreated central nervous system (CNS) metastases.

          7. Active infection within 2 weeks.

          8. Know to be allergic to the ingredients of SHR-1702 injection.

          9. Prior allogeneic bone marrow transplantation or solid organ transplant

         10. With a history or current evidence of any condition, therapy, or laboratory
             abnormality that might confound the results of the study, interfere with the subject's
             participation for the full duration of the study, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bo Jiang, M.D.</last_name>
    <phone>86-022-23909095</phone>
    <email>jiangbo044@163.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

